ABBV - AbbVie working with FDA after reports of fake Botox versions
2024-04-16 10:47:43 ET
More on AbbVie
- AbbVie: Great To Be Proven Wrong - Still Not A Buy
- AbbVie: Bulletproof Fundamentals
- AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
- AbbVie keeps Humira market share near 100% despite biosimilars: report
- GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma